MCID: MGR001
MIFTS: 49

Migraine Without Aura

Categories: Genetic diseases, Neuronal diseases

Aliases & Classifications for Migraine Without Aura

MalaCards integrated aliases for Migraine Without Aura:

Name: Migraine Without Aura 12 6 43 15 17
Common Migraine 12 71
Migraine Without Aura, Susceptibility to 6

Classifications:



External Ids:

Disease Ontology 12 DOID:12783
ICD9CM 34 346.1
MeSH 43 D020326
NCIt 49 C117004
SNOMED-CT 67 56097005
ICD10 32 G43.0
UMLS 71 C0338480

Summaries for Migraine Without Aura

Disease Ontology : 12 A migraine that is characterized by migraine headaches that are not accompanied by an aura.

MalaCards based summary : Migraine Without Aura, also known as common migraine, is related to headache and familial hemiplegic migraine. An important gene associated with Migraine Without Aura is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways are Circadian entrainment and Dopamine-DARPP32 Feedback onto cAMP Pathway. The drugs Norepinephrine and Levomilnacipran have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Migraine Without Aura

Diseases in the Migraine Without Aura family:

Migraine with or Without Aura 1 Migraine with or Without Aura 2
Migraine with or Without Aura 3 Migraine Without Aura 4
Migraine with or Without Aura 5 Migraine with or Without Aura 6
Migraine with or Without Aura 8 Migraine with or Without Aura 10
Migraine with or Without Aura 11 Migraine with or Without Aura 12
Migraine with or Without Aura 13

Diseases related to Migraine Without Aura via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 162)
# Related Disease Score Top Affiliating Genes
1 headache 32.0 SCN1A NOTCH3 KCNK18 EDNRA
2 familial hemiplegic migraine 31.1 SCN1A NOTCH3 KCNK18
3 migraine with aura 30.9 TRPM8 SLC6A4 SCN1A PRDM16 NOTCH3 MTHFR
4 alexithymia 30.9 SLC6A4 HTR1A DRD2
5 generalized anxiety disorder 30.5 SLC6A4 HTR1A DRD2
6 sleep disorder 30.5 TNF SLC6A4 PRL HTR1A DRD2
7 restless legs syndrome 30.4 SLC6A4 PRL DRD4 DRD3 DRD2
8 fibromyalgia 30.3 TNF SLC6A4 PRL HTR1A DRD2
9 migraine, familial hemiplegic, 2 30.3 SCN1A KCNK18 ASTN2
10 migraine with or without aura 1 30.2 TRPM8 TNF SLC6A4 SCN1A PRL PRDM16
11 panic disorder 30.2 SLC6A4 PRL HTR1A DRD4 DRD3 DRD2
12 stroke, ischemic 29.9 TNF NOTCH3 MTHFR EDNRA
13 bipolar disorder 29.0 TNF SLC6A4 PRL MTHFR HTR1A GRIA1
14 migraine without aura 4 12.7
15 migraine, familial hemiplegic, 3 11.4
16 migraine with or without aura 13 11.4
17 carotidynia 11.1
18 oculogyric crisis 10.5 DRD4 DRD3 DRD2
19 chronic tic disorder 10.5 DRD4 DRD3 DRD2
20 polysubstance abuse 10.5 DRD3 DRD2
21 galactorrhea 10.5 PRL DRD2
22 night blindness, congenital stationary, type 1h 10.5 DRD4 DRD3 DRD2
23 opioid abuse 10.5 DRD4 DRD3 DRD2
24 tardive dyskinesia 10.5 DRD3 DRD2
25 charcot-marie-tooth disease, dominant intermediate f 10.5 DRD4 DRD3 DRD2
26 lingual-facial-buccal dyskinesia 10.5 DRD4 DRD3 DRD2
27 choreatic disease 10.5 DRD4 DRD3 DRD2
28 migraine, familial hemiplegic, 1 10.5 SLC6A4 SCN1A KCNK18
29 prolactin producing pituitary tumor 10.4 PRL DRD2
30 oppositional defiant disorder 10.4 SLC6A4 DRD4 DRD2
31 heroin dependence 10.4 SLC6A4 DRD4 DRD2
32 neuroleptic malignant syndrome 10.4 HTR1A DRD3 DRD2
33 intermittent explosive disorder 10.4 SLC6A4 HTR1A DRD2
34 radiation proctitis 10.4 TNF EDNRA
35 neurotic disorder 10.4 TNF SLC6A4 HTR1A
36 drug psychosis 10.4 HTR1A DRD4 DRD3 DRD2
37 drug-induced mental disorder 10.4 HTR1A DRD4 DRD3 DRD2
38 depression 10.4 SLC6A4 HTR1A GRIA1
39 substance-induced psychosis 10.4 HTR1A DRD4 DRD3 DRD2
40 conduct disorder 10.4 SLC6A4 DRD4 DRD2
41 phobic disorder 10.4 SLC6A4 HTR1A DRD2
42 opiate dependence 10.4 SLC6A4 DRD4 DRD3 DRD2
43 schizophreniform disorder 10.4 PRL DRD4 DRD3 DRD2
44 trichotillomania 10.4 PRL DRD4 DRD3 DRD2
45 chronic pulmonary heart disease 10.4 TNF SLC6A4 EDNRA
46 hyperprolactinemia 10.4 PRL DRD4 DRD2
47 inhibited male orgasm 10.4 SLC6A4 HTR1A
48 somatoform disorder 10.4 TRPM8 TNF SLC6A4 SCN1A
49 amphetamine abuse 10.4 SLC6A4 DRD4
50 gastroparesis 10.3 PRL DRD4 DRD3 DRD2

Comorbidity relations with Migraine Without Aura via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Migraine Without Aura:



Diseases related to Migraine Without Aura

Symptoms & Phenotypes for Migraine Without Aura

MGI Mouse Phenotypes related to Migraine Without Aura:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 DRD2 DRD3 DRD4 EDNRA GRIA1 HTR1A
2 homeostasis/metabolism MP:0005376 10.07 DRD2 DRD3 DRD4 EDNRA GRIA1 HTR1A
3 cardiovascular system MP:0005385 10.02 DRD2 DRD3 EDNRA HTR1A MEF2D NOTCH3
4 integument MP:0010771 9.9 ASTN2 DRD2 EDNRA GRIA1 MTHFR NOTCH3
5 nervous system MP:0003631 9.86 DRD2 DRD3 DRD4 EDNRA GRIA1 HTR1A
6 skeleton MP:0005390 9.28 DRD2 EDNRA GRIA1 MEF2D MTHFR NOTCH3

Drugs & Therapeutics for Migraine Without Aura

Drugs for Migraine Without Aura (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 155)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norepinephrine Approved Phase 4 51-41-2 439260
2
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
3
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
4
Topiramate Approved Phase 4 97240-79-4 5284627
5
Promethazine Approved, Investigational Phase 4 60-87-7 4927
6
Histamine Approved, Investigational Phase 4 51-45-6 774
7
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
8
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
9
Almotriptan Approved, Investigational Phase 4 181183-52-8, 154323-57-6 123606
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
11
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
12
Acetaminophen Approved Phase 4 103-90-2 1983
13
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
14
Ibuprofen Approved Phase 4 15687-27-1 3672
15
Haloperidol Approved Phase 4 52-86-8 3559
16 Antidepressive Agents Phase 4
17 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
18 Neurotransmitter Agents Phase 4
19 Hypoglycemic Agents Phase 4
20 Anticonvulsants Phase 4
21 Gastrointestinal Agents Phase 4
22 Anesthetics Phase 4
23 Hypnotics and Sedatives Phase 4
24 Serotonin Receptor Agonists Phase 4
25 Anti-Allergic Agents Phase 4
26 Histamine Antagonists Phase 4
27 Antiemetics Phase 4
28 Histamine H1 Antagonists Phase 4
29
Histamine Phosphate Phase 4 51-74-1 65513
30 Anesthetics, Local Phase 4
31 Dermatologic Agents Phase 4
32 Analgesics, Non-Narcotic Phase 4
33 Analgesics Phase 4
34 Cyclooxygenase Inhibitors Phase 4
35 Anti-Inflammatory Agents, Non-Steroidal Phase 4
36 Antirheumatic Agents Phase 4
37 Psychotropic Drugs Phase 4
38 Pharmaceutical Solutions Phase 4
39 Dopamine Agents Phase 4
40 Analgesics, Opioid Phase 4
41 Dopamine Antagonists Phase 4
42 Narcotics Phase 4
43 Anesthetics, General Phase 4
44 Anesthetics, Intravenous Phase 4
45 Antipyretics Phase 4
46 Ketorolac Tromethamine Phase 4
47 Dexketoprofen trometamol Phase 4
48 Antipsychotic Agents Phase 4
49 Haloperidol decanoate Phase 4
50
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202

Interventional clinical trials:

(show top 50) (show all 82)
# Name Status NCT ID Phase Drugs
1 Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine. Unknown status NCT01319825 Phase 4 milnacipran
2 Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial Completed NCT02314351 Phase 4 Metoclopramide 10 mg;Placebo;Fentanyl
3 Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate) Completed NCT00210496 Phase 4 topiramate; almotriptan malate
4 TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study Completed NCT00212810 Phase 4 Topiramate
5 Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department Completed NCT01596166 Phase 4 Ketorolac Tromethamine;Metoclopramide
6 The Effects of Acetaminophen and Ibuprofen With and Without Magnesium in the Treatment of Primary Migraine in Childhood Completed NCT01756209 Phase 4 Magnesium 400Mg;Ibuprofen 10 mg/kg;acetaminophen 15 mg/kg
7 The Comparison of the Effectiveness of Intravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack in Emergency Service Completed NCT01730326 Phase 4 Paracetamol;Dexketoprofen
8 Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the Emergency Department: A Randomized Controlled Trial Completed NCT02098499 Phase 4 Haloperidol;Metoclopramide 10mg;Diphenhydramine
9 Randomised Sham-controlled Trial of Anodal Transcranial Direct Current Stimulation (tDCS) for the Prevention of Episodic Migraine Unknown status NCT02122757 Phase 3
10 A 12-week Prospective, Double-blinded, Randomized, Multicenter Study of Low Dose and Medium Dose Botulinum Toxin Type A (Dysport® ) Injection for Migraine Prophylaxis. Completed NCT00258609 Phase 3 Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection
11 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine Completed NCT00236509 Phase 3 topiramate
12 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate in the Prophylaxis of Migraine Completed NCT00231595 Phase 3 topiramate
13 Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment: a Randomized, Double Blind Clinical Trial Completed NCT01814189 Phase 3 Sumatriptan+Promethazine (SPr)
14 A Randomized, Double-Blind, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prophylaxis of Migraine Completed NCT00236561 Phase 3 topiramate, propranolol
15 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Tolerability of TREXIMA* (Sumatriptan Succinate/Naproxen Sodium) for a Single Moderate or Severe Headache in Adults Diagnosed With Probable Migraine Without Aura (ICHD-II 1.6.1) (*TREXIMET) Completed NCT00387881 Phase 3 sumatriptan succinate / naproxen sodium;Placebo
16 Candesartan vs Propranolol for Migraine Prevention: A Double Blind, Placebo Controlled, Double Dummy, Triple Cross-over Study Completed NCT00884663 Phase 2, Phase 3 Candesartan;propranolol;placebo
17 A Multi-Center, Randomized, Parallel, Double-Blind, Placebo-Controlled Study in Evaluation the Efficacy and Safety of Laxymig® ER as Prophylactic Treatment in Patients With Migraine Completed NCT00334178 Phase 3 Laxymig ER (drug)
18 A Multicentre, Dose Optimisation Study to Assess the Consistency of Efficacy of Eletriptan for the Treatment of Migraine (With and Without Aura) Completed NCT01859481 Phase 3 Placebo;Eletriptan HBr 40 mg;Eletriptan HBr 80 mg
19 Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache Completed NCT00471952 Phase 3 Maxalt 10mg MLT plus Caffeine 75mg;Maxalt 10mg MLT plus Placebo;Placebo + Placebo
20 Parenteral Corticosteroids as Adjuvant Therapy for Migraine Headaches Completed NCT00122278 Phase 3 Dexamethasone
21 EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine Active, not recruiting NCT03901482 Phase 3 Dihydroergotamine;Placebos
22 An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine Not yet recruiting NCT04406649 Phase 3 Dihydroergotamine
23 Safety and Efficacy of De-Novo Algorithm and Formula in the Treatment of Patients With Intractable Chronic Craniofacial Neuralgia, or Chronic Migraine Headaches. Unknown status NCT03220113 Phase 1, Phase 2
24 Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study Unknown status NCT00285402 Phase 2 AST-726 Low dose;AST-726 High dose;AST-726 Placebo
25 Multi-centre, Parallel Group, Double-blind, Placebo Controlled Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Completed NCT00311662 Phase 2 Tonabersat;Placebo
26 A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Efficacy, Safety and Tolerability Study of Dronabinol MDI in the Acute Treatment of Migraine Headache Completed NCT00123201 Phase 2 Dronabinol MDI
27 Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache Without Aura Completed NCT00959751 Phase 2 NXN-188;Placebo
28 Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Migraine. Safety Issues. Completed NCT02259075 Phase 1, Phase 2 Botulinum Toxin Type A
29 Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension Completed NCT00534560 Phase 2 Tonabersat;Tonabersat;Placebo
30 Effects of DFN-15 on Migraine With Allodynia Completed NCT03472378 Phase 2 DFN-15
31 Investigator-Initiated, Proof-of-Concept, Phase 2, Randomized Controlled Trial to Assess a Single Dose of Low-Dose Naltrexone and Acetaminophen (LDNA) Combination and Its Individual Components in the Acute Treatment of Migraine Completed NCT03061734 Phase 2 Naltrexon/Acetaminophen;Naltrexone/Acetaminophen-High Dose;Naltrexone Alone (regular dose);Acetaminophen Alone;Matching Placebo
32 A Randomized, Double-blind Placebo-controlled, Parallel Group Study to Study the Efficacy and Tolerability of Ramelteon (Rozerem) in the Prophylaxis of Migraine Terminated NCT00739024 Phase 2 Ramelteon;Placebo
33 Dexamethasone for the Treatment of Established Postoperative Nausea and Vomiting - a Randomised, Placebo-controlled, Dose-finding Study Terminated NCT01975727 Phase 2 Placebo;Dexamethasone 3 mg;Dexamethasone 6 mg;Dexamethasone 12 mg
34 A Randomized, Open-Label, Crossover Study to Evaluate the PK, Bioavailability, Dose Proportionality, Safety, and Tolerability of Single Doses of STS101, DHE Mesylate IM Injection and DHE Mesylate Nasal Spray in Healthy Adult Subjects Completed NCT03874832 Phase 1 Dihydroergotamine
35 A Phase 1, Two-part, Single Dose, Randomised, Double-blind, Placebo-controlled Parallel Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Subcutaneous TRV250 Following Glyceryl Trinitrate Infusion Recruiting NCT04201080 Phase 1 Part A: TRV250-20mg/ml;Placebo;Part B: TRV250 Dose 1;Part B: TRV250 Dose 2;Part B: TRV250 Dose 3;Placebo
36 Multiparametric Diagnostic Model of Thick-section Clinical-quality MRI Data in Detecting Migraine Without Aura Unknown status NCT03570086
37 Cortical Reorganisation in Patients With Primary Headache Disorders Unknown status NCT00263991
38 Investigation of Vascular Inflammation in Migraine Without Aura Using Molecular Nano-imaging and Black Blood Imaging MRI Unknown status NCT02549898 Feraheme;Cilostazol
39 Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI Unknown status NCT02202486
40 Identification of Inflammatory Markers in Migraine Patients Unknown status NCT00969995
41 Inflammatory Markers Identification in Migraine Patients Unknown status NCT01618201
42 Pituitary Adenylate Cyclase-activating Polypeptide (PACAP27) Headache Properties in Migraine Without Aura Patients Completed NCT03471039 PACAP27;Saline
43 Basic Scientific Research Investigating PACAP38 Headache Inducing Effects in Migraine Patients Completed NCT00380263 PACAP38
44 Functional MRI (fMRI) in Patients With Migraine Without Aura Provoked by Completed NCT00363532 infusion of calcitonin gene related peptide (CGRP)
45 Glutamate Concentrations in the Brain Over the Course of a Migraine-like Attack Completed NCT04220606 Glyceryl trinitrate (I.V. infusion 0.5 µg/kg/min over 20 min)
46 The Effect of PACAP38 and VIP on Migraine Patients Assessed by a 3-Tesla MR Scanner Completed NCT01471990 Pituitary Adenylate Cyclase-Activating Polypeptide-38;Vasoactive Intestinal Peptide
47 Amylin and CGRP Migraine Provocation in Migraine Without Aura Patients Completed NCT03598075
48 The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache. Development of a Pragmatic Migraine Model Completed NCT02486276 Cilostazol;Sumatriptan;Placebo
49 Transcriptomic and Biochemical Changes During Spontaneous Attacks of Migraine With Aura and Migraine Without Aura Completed NCT02468622
50 The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache Completed NCT03422796 Cilostazol 200mg;SUMAtriptan 6 MG/ML;Placebo

Search NIH Clinical Center for Migraine Without Aura

Cochrane evidence based reviews: migraine without aura

Genetic Tests for Migraine Without Aura

Anatomical Context for Migraine Without Aura

MalaCards organs/tissues related to Migraine Without Aura:

40
Brain, Testes, Cortex, Pituitary, Endothelial, Heart, Skin

Publications for Migraine Without Aura

Articles related to Migraine Without Aura:

(show top 50) (show all 2136)
# Title Authors PMID Year
1
Association between the tumor necrosis factor-alpha -308 G/A gene polymorphism and migraine. 61 6
14718719 2004
2
Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. 6
16418737 2006
3
An association between asthma and TNF-308G/A polymorphism: meta-analysis. 6
16865291 2006
4
Association of tumor necrosis factor polymorphisms with asthma and serum total IgE. 6
14681301 2004
5
Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. 6
12746914 2003
6
Association between G-308A polymorphism of the tumor necrosis factor-alpha gene and 24-hour ambulatory blood pressure values in type 1 diabetic adolescents. 6
12485196 2002
7
Association of polymorphisms and allelic combinations in the tumour necrosis factor-alpha-complement MHC region with coronary artery disease. 6
11826025 2002
8
Relation between tumour necrosis factor polymorphism TNFalpha-308 and risk of asthma. 6
11896460 2002
9
Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. 6
11506397 2001
10
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. 6
11261930 2001
11
Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. 6
10450718 1999
12
Genetic contribution of the tumor necrosis factor region in Guillain-Barré syndrome. 6
9818939 1998
13
Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM. 6
8056188 1994
14
Genetics of migraine aura: an update. 61
32503413 2020
15
Cognitive Networks Disarrangement in Patients With Migraine Predicts Cutaneous Allodynia. 61
32533895 2020
16
Preference for Lighting Chromaticity in Migraine With Aura. 61
32282067 2020
17
Objective Diagnosis of Migraine without Aura with Migraine Vascular Index: A Novel Formula to Assess Vasomotor Reactivity. 61
32146006 2020
18
Altered resting-state functional connectivity between subregions in the thalamus and cortex in migraine without aura. 61
32562320 2020
19
Association of Migraine With Aura and Other Risk Factors With Incident Cardiovascular Disease in Women. 61
32515815 2020
20
Neurochemical metabolite alterations of the occipital lobe in migraine without aura by proton magnetic resonance spectroscopy. 61
32573358 2020
21
Glutamate levels and perfusion in pons during migraine attacks: A 3T MRI study using proton spectroscopy and arterial spin labeling. 61
32423331 2020
22
A subjective cognitive impairments scale for migraine attacks: validation of the Italian version of the MIG-SCOG. 61
31897947 2020
23
Subdiagnosis, but not presence of vestibular symptoms, predicts balance impairment in migraine patients - a cross sectional study. 61
32448118 2020
24
Paracetamol versus Ibuprofen for the Acute Treatment of Migraine Headache in Children: A Blinded Randomized Controlled Trial. 61
32451827 2020
25
Disrupted functional connectivity between sub-regions in the sensorimotor areas and cortex in migraine without aura. 61
32375638 2020
26
Bilateral stellate ganglion block for migraine: A case report. 61
32358380 2020
27
Manifestation of migraine in adolescents: Does it change in puberty? 61
32115367 2020
28
Phenotypic Variability in Leukoencephalopathy with Brain Calcifications and Cysts: Case Report of Siblings from an Irish Traveller Family with a Homozygous SNORD118 Mutation. 61
32361877 2020
29
Acceptance and Commitment Therapy (ACT) vs Erenumab for High Frequency Episodic Migraine Without Aura: Time to Take the Gloves Off! 61
32096558 2020
30
A prospective study on osmophobia in migraine versus tension-type headache in a large series of attacks. 61
31537108 2020
31
Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. 61
32056462 2020
32
Short-latency afferent inhibition and somato-sensory evoked potentials during the migraine cycle: surrogate markers of a cycling cholinergic thalamo-cortical drive? 61
32299338 2020
33
Migrainous facial palsy (MFP): the introduction of a new concept of neurovascular conflict and its preliminary clinical evidence. 61
32239343 2020
34
Pyridoxine, folate and cobalamin for migraine: A systematic review. 61
32279306 2020
35
Temporal instability of salience network activity in migraine with aura. 61
31815918 2020
36
Persistent Post-Traumatic Headache and Migraine: Pre-Clinical Comparisons. 61
32283843 2020
37
Neck pain: is it part of a migraine attack or a trigger before a migraine attack? 61
30392067 2020
38
Relationship between migraine headache and hematological parameters. 61
32347450 2020
39
Migraine and Arterial Stiffness in the Brazilian Longitudinal Study of Adult Health: ELSA-Brasil. 61
31907516 2020
40
Premonitory symptoms in glyceryl trinitrate triggered migraine attacks: a case-control study. 61
32332251 2020
41
Major depression subtypes are differentially associated with migraine subtype, prevalence and severity. 61
31645113 2020
42
Subgrouping Factors Influencing Migraine Intensity in Women: A Semi-automatic Methodology Based on Machine Learning and Information Geometry. 61
31677218 2020
43
Evaluation of retinal microvasculature and foveal avascular zone by the optical coherence tomography angiography in pediatric migraine patients. 61
32157669 2020
44
Changes in face and face pareidolia processing in patients with migraine: an ERP study. 61
31940235 2020
45
Clinical features of right-to-left shunt in the different subgroups of migraine. 61
32011802 2020
46
A pilot exploratory study comparing the King-Devick test (KDT) during and between migraine attacks. 61
31660762 2020
47
Enhanced pre-ictal cortical responsivity in migraine patients assessed by visual chirp stimulation. 61
32188264 2020
48
Sensory Hypersensitivity Symptoms in Migraine With vs Without Aura: Results From the American Registry for Migraine Research. 61
31965576 2020
49
Abnormal cardiovascular response to nitroglycerin in migraine. 61
31594384 2020
50
Acupuncture for menstrual migraine: a systematic review. 61
32122964 2020

Variations for Migraine Without Aura

ClinVar genetic disease variations for Migraine Without Aura:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 NOTCH3 NM_000435.3(NOTCH3):c.505C>T (p.Arg169Cys)SNV Pathogenic 9219 rs28933696 19:15302945-15302945 19:15192134-15192134
2 TNF TNF, -308G-ASNV risk factor 12388

Expression for Migraine Without Aura

Search GEO for disease gene expression data for Migraine Without Aura.

Pathways for Migraine Without Aura

GO Terms for Migraine Without Aura

Cellular components related to Migraine Without Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 9.97 TRPM8 TNF SLC6A4 SCN1A NOTCH3 KCNK18
2 integral component of plasma membrane GO:0005887 9.56 TNF SLC6A4 KCNK18 HTR1A EDNRA DRD4
3 dopaminergic synapse GO:0098691 9.26 DRD3 DRD2
4 synapse GO:0045202 9.17 SLC6A4 PHACTR1 MTHFR HTR1A GRIA1 DRD3

Biological processes related to Migraine Without Aura according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.95 SLC6A4 MTHFR DRD3 DRD2
2 response to hypoxia GO:0001666 9.89 SLC6A4 MTHFR EDNRA DRD2
3 cellular calcium ion homeostasis GO:0006874 9.82 TRPM8 DRD4 DRD3
4 response to toxic substance GO:0009636 9.81 SLC6A4 DRD3 DRD2
5 social behavior GO:0035176 9.76 SLC6A4 DRD4 DRD3
6 response to amphetamine GO:0001975 9.72 DRD4 DRD3 DRD2
7 negative regulation of protein secretion GO:0050709 9.67 DRD4 DRD3 DRD2
8 negative regulation of cytosolic calcium ion concentration GO:0051481 9.65 DRD3 DRD2
9 arachidonic acid secretion GO:0050482 9.65 DRD4 DRD3 DRD2
10 prepulse inhibition GO:0060134 9.64 DRD3 DRD2
11 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.64 DRD3 DRD2
12 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.63 DRD3 DRD2
13 dopamine receptor signaling pathway GO:0007212 9.63 DRD4 DRD3 DRD2
14 positive regulation of renal sodium excretion GO:0035815 9.62 DRD3 DRD2
15 G protein-coupled receptor internalization GO:0002031 9.62 DRD3 DRD2
16 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.61 DRD4 DRD3
17 regulation of potassium ion transport GO:0043266 9.61 DRD3 DRD2
18 behavioral response to cocaine GO:0048148 9.61 DRD4 DRD3 DRD2
19 regulation of dopamine metabolic process GO:0042053 9.6 HTR1A DRD4
20 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.58 DRD3 DRD2
21 synaptic transmission, dopaminergic GO:0001963 9.58 DRD4 DRD3 DRD2
22 regulation of neurotransmitter uptake GO:0051580 9.57 DRD3 DRD2
23 negative regulation of dopamine receptor signaling pathway GO:0060160 9.56 DRD3 DRD2
24 regulation of locomotion involved in locomotory behavior GO:0090325 9.54 DRD3 DRD2
25 vasoconstriction GO:0042310 9.54 SLC6A4 HTR1A EDNRA
26 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.52 DRD4 DRD2
27 acid secretion GO:0046717 9.51 DRD3 DRD2
28 negative regulation of voltage-gated calcium channel activity GO:1901386 9.5 DRD4 DRD3 DRD2
29 behavioral response to ethanol GO:0048149 9.43 DRD4 DRD3 DRD2
30 dopamine metabolic process GO:0042417 9.33 DRD4 DRD3 DRD2
31 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.13 DRD4 DRD3 DRD2
32 response to histamine GO:0034776 8.8 DRD4 DRD3 DRD2

Molecular functions related to Migraine Without Aura according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.43 DRD4 DRD3 DRD2
2 dopamine binding GO:0035240 9.33 DRD4 DRD3 DRD2
3 serotonin binding GO:0051378 9.32 SLC6A4 HTR1A
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.13 DRD4 DRD3 DRD2
5 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD4 DRD3 DRD2

Sources for Migraine Without Aura

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....